Finally, tyrosine kinase inhibitors (TKIs) demonstrated partial responses in VHL-related tumors, particularly RCC and pancreatic lesions, with acceptable side effects in a study by the Medical Ethics Committee of Peking University [182]. The gene discussed is VHL; the disease is renal cell carcinoma.